UNLIMITED TURBO SHORT - NOVO-NORDISK B | Real-time Euronext Paris 10:48:12 2024-07-12 am EDT | ||
| 2.51 EUR | -8.06% |
|
| Current month | +26.98% | ||
| 1 month | +12.35% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 24-07-12 | 2.51 | -8.06% |
| 24-07-11 | 2.73 | +7.91% |
| 24-07-10 | 2.53 | -3.80% |
| 24-07-09 | 2.63 | +10.04% |
| 24-07-08 | 2.39 | -5.16% |
Real-time Euronext Paris
Last update July 12, 2024 at 10:48 am EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| US4NB | |
| ISIN | NLBNPNL2O2A7 |
| Date issued | 2024-02-26 |
| Strike | 1,145 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 4.01 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.805 € |
|---|---|
| Lowest since issue | 1.82 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
967.3
DKK
Average target price
956.5
DKK
Spread / Average Target
-1.11%
- Stock Market
- Certificates
- US4NB Certificat
